AKT1 and cancer: Almost identical observations were reported in colorectal cancer, where the expression of DAB2IP sensitized cancer cells to cisplatin, oxaliplatin, and doxorubicin, and inhibited tumor growth in mouse xenografts, with reduced AKT and ERK activation [42].